Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GlycoVaxyn

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug

Positive opinions for GSK's IL-5 antibody and Novartis' potential $5bn-a-year brand

- PMLiVE

GSK sets its sights high for MyAsthma app

Firm wants its mobile app to be one of the best available for any disease

- PMLiVE

ViiV boosted by positive phase III results for HIV drug Triumeq

Data reaffirms benefitsof drug in comparison to current antiretroviral medications 

- PMLiVE

Boehringer COPD drug ‘could give patients more independence’

New data shows Stiolto improves patients’ lives

- PMLiVE

AstraZeneca expands antisense alliance with Isis

Builds on existing deal that sees the firm develop new medicines for a host of diseases

- PMLiVE

Hints of recovery at GSK as group sales climb

Drug revenue still falling but vaccines and HIV drugs help offset Advair decline

dengue fever mosquito

World first as CHMP backs GSK malaria vaccine Mosquirix

The EMA's scientific advisers recommend its useoutside Europe

- PMLiVE

GSK partners with new science hub the Francis Crick Institute

Will work with the biomedical facility on an 'open innovation' basis

- PMLiVE

Horizon launches $3bn hostile bid for Depomed

Horizon wants to add Depomed’s pain therapies and CNS drugs to its products

- PMLiVE

Teva planning fresh offer for Mylan, say sources

Israeli firm has already made multiple informal bids

China flag thumb

HIV deal in China helps GSK rebuild tattered reputation

Country to receive discounted supplies of HIV drug Tivicay

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links